- Conference Call Scheduled for 5:00 PM ET, Thursday, November 8^th -

DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that the Company will report its financial results for the third quarter of 2012 on Thursday, November 8, 2012 after market close. The announcement of results will be followed by a conference call with the investment community on the same day at 5:00 PM ET.

Navidea's President and CEO, Dr. Mark Pykett, Executive Vice President and Chief Business Officer, Dr. Thomas Tulip, and Senior Vice President and CFO, Brent Larson, will provide a development and business update and will discuss the Company's financial results for the third quarter of 2012 during the conference call. The conference call can be accessed as follows:

About Navidea Biopharmaceuticals, Inc.

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing four radiopharmaceutical agent platforms Lymphoseek^®, NAV4694, NAV5001 (CFT) and RIGScan^TM  to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and, ultimately, patient care. Navideas strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Companys pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.

Navidea Biopharmaceuticals, Inc.
Brent Larson, Sr. VP & CFO, 614-822-2330

Source: Navidea Biopharmaceuticals, Inc.